Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Orexigen Therapeutics, Inc
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. ≥50 years of age (women) or ≥45 years of age (men)
2. Body mass index (BMI) ≥27 kg/m2 and ≤50 kg/m2
3. Waist circumference ≥88 cm (women) or ≥102 cm (men)
4. At increased risk of adverse cardiovascular outcomes:
* Cardiovascular disease (confirmed diagnosis or at high likelihood of cardiovascular disease) with at least one of the following:
* History of documented myocardial infarction \>3 months prior to screening
* History of coronary revascularization
* History of carotid or peripheral revascularization
* Angina with ischemic changes (resting ECG), ECG changes on a graded exercise test (GXT), or positive cardiac imaging study
* Ankle brachial index \<0.9 (by simple palpation) within prior 2 years
* ≥50% stenosis of a coronary, carotid, or lower extremity artery within prior 2 years
AND/OR
Type 2 diabetes mellitus with at least 2 of the following:
* Hypertension (controlled with or without pharmacotherapy at \<145/95 mm Hg)
* Dyslipidemia requiring pharmacotherapy
* Documented low HDL cholesterol (\<50 mg/dL in women or \<40 mg/dL in men) within prior 12 months
* Current tobacco smoker
You may not be if
1. Myocardial infarction within 3 months prior to screening
2. Angina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading scheme
3. Clinical history of cerebrovascular disease (stroke)
4. History of tachyarrhythmia other than sinus tachycardia
5. Planned bariatric surgery, cardiac surgery, or coronary angioplasty
6. History of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the subject to seizures
7. History of mania or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary)
8. Any condition with life expectancy anticipated to be less than 4 years (e.g., congestive heart failure NYHA Class 3 or 4)
Clareo Health | Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
